LentiGlobin, a gene therapy for sickle cell disease granted MHRA ‘innovation passport’

The ‘innovation passport’ pathway, launched in January, offers a new UK approval process which aims to reduce the time to market for innovative medicines. LentiGlobin is being investigated for sickle cell disease in the Phase III HGB-210 study.

Source:

PharmaTimes